Angiogenesis is known to be required for growth of tumors larger than a few millimeters (4), and agents that selectively inhibit endothelial cells have been shown to limit tumor growth (5, 6). Further, endothelial cells are attractive therapeutic targets because they have greater genomic stability than cancer cells and are less likely to rapidly develop resistance (7).
T HE ACTIVE FORM of vitamin D, 1␣,25-dihydroxyvita-
min D 3 [1, 2 D 3 ] is a key regulator of calcium homeostasis (1) and has antitumor activity in a wide variety of tumor types (2) . Low nanomolar concentrations of 1,25-(OH) 2 D 3 can directly inhibit the proliferation of several types of cancer cells (2, 3) . Interestingly, we have observed that 1,25-(OH) 2 D 3 also inhibits the growth of tumors generated by a prostate cancer cell line that is relatively resistant to 1,25-(OH) 2 D 3 in vitro (Yu, W.-D., and C. S. Johnson, unpublished observations). A possible explanation for these results is that 1,25-(OH) 2 D 3 acts by inhibiting angiogenesis in these tumors. Angiogenesis is known to be required for growth of tumors larger than a few millimeters (4) , and agents that selectively inhibit endothelial cells have been shown to limit tumor growth (5, 6) . Further, endothelial cells are attractive therapeutic targets because they have greater genomic stability than cancer cells and are less likely to rapidly develop resistance (7) .
Previous reports support the hypothesis that 1,25-(OH) 2 D 3 inhibits tumor angiogenesis. Expression of the vitamin D receptor (VDR) has been observed in endothelial cells (8) , and 1,25-(OH) 2 D 3 and its analogs inhibit embryonic angiogenesis in chick chorioallantoic membranes (9) . Decreased vessel density and VEGF expression have also been observed in various tumor models after treatment with 1,25-(OH) 2 D 3 (10, 11 ). An inhibitory effect for 1,25-(OH) 2 D 3 against VEGFstimulated growth of bovine aortic endothelial cells has also been observed, as well as inhibition of sprouting and elongation (12) . However, the responsiveness of endothelial cells that originate from tumors has not been examined directly.
We and others have previously isolated tumor-derived endothelial cells (TDECs) and shown that they differ in several ways from endothelial cells derived from normal tissues (13) (14) (15) (16) ; therefore, all endothelial cells may not respond the same to 1,25-(OH) 2 D 3 . Here, we examined the antiproliferative effects of 1,25-(OH) 2 D 3 in TDECs and endothelial cells derived from normal tissues.
As use of 1,25-(OH) 2 D 3 as a single agent is limited by its hypercalcemic effects (17) (18) (19) , we also investigated the effects of three vitamin D analogs, which are less hypercalcemic, on TDECs. In addition, we tested the ability of the combination of 1,25-(OH) 2 D 3 and dexamethasone (DEX) to inhibit the proliferation of TDECs, as we have shown that DEX enhances the antitumor activity and reduces the toxicity of 1,25-(OH) 2 D 3 (20) . Further, we compared the expression of VDR and effects on growth and survival signaling pathways in TDECs and endothelial cells derived from normal tissues. Finally, we examined the possibility that 1,25-(OH) 2 D 3 affects angiogenic signaling between cancer cells and endothelial cells. 
Materials and Methods

Chemicals and reagents
Cells and model systems
The squamous cell carcinoma (SCC) VII/SF murine SCC cells, which were derived from a spontaneously arising tumor of the C3H mouse (21) , and radiation-induced fibrosarcoma-1 (RIF-1) cells, which were derived from a RIF in the C3H mouse (22) , were maintained in RPMI 1640 supplemented with 14% FBS and 1% penicillin-streptomycin sulfate.
We previously reported the isolation and characterization of TDECs from both the RIF-1 (13) and SCC VII/SF (15) tumor models. Briefly, tumors were harvested, and a single cell suspension was prepared using an enzyme cocktail including collagenases and ribonucleases. Cells were stained with antibodies specific for the endothelial cell markers, angiotensin-converting enzyme for RIF-1 and platelet-endothelial cell adhesion molecule for SCC, followed by a fluorescein isothiocyanate-linked secondary antibody. Cells were then sorted by fluorescence-activated flow cytometry based on the level of fluorescein isothiocyanate staining. Murine yolk sac endothelial cells (MYSEC) and murine aortic endothelial cells (MAE) cells were a gift from Dr. Robert Auerbach (University of Wisconsin, Madison, WI) and were derived using a similar method. For all experiments, the endothelial cells were grown in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin sulfate on 1% gelatin-conditioned plastic.
Crystal violet assay
As described previously (3), cells were plated in 96-well plates and allowed to attach for 24 h before treatments were added. Cells were then incubated for 72 h before harvesting by staining with crystal violet, and the OD was read at 540 nm. The percent inhibition was calculated using the following equation: (1 Ϫ [(OD treated Ϫ OD background )/(OD control Ϫ OD background )]) ϫ 100 ϭ % inhibition.
In vitro treatments, preparation of whole cell lysates, and Western blot analysis
Sample preparation and Western blot analysis were performed essentially as described previously (23) . Antibodies used include polyclonal rabbit anti-VDR (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), polyclonal rabbit antimouse p21 (BD Pharmingen, San Diego, CA), polyclonal rabbit antimouse p27 Kip1 (BD Pharmingen), mouse monoclonal anti-phospho-ERK (Santa Cruz Biotechnology, Inc.), polyclonal rabbit antiphospho-Akt (Ser 473 ; Cell Signaling Technology, Beverly, MA), purified mouse antihuman Rb (BD Pharmingen), mouse monoclonal antip53 (Santa Cruz Biotechnology, Inc.), polyclonal rabbit anti-Fas (Santa Cruz Biotechnology, Inc.), mouse monoclonal anti-poly(ADP-ribose) polymerase (anti-PARP; Enzyme Systems Products, Livermore, CA), and purified rabbit antimouse angiopoietin-2 (APC-2; Calbiochem, San Diego, CA). Antirabbit and antimouse horseradish peroxidase-conjugated secondary antibodies (Amersham Pharmacia Biotech, Arlington Heights, IL) were used.
Results
1,25-(OH) 2 D 3 inhibits the proliferation of tumor-derived endothelial cells
We used a crystal violet assay to test the antiproliferative effects of 1,25-(OH) 2 D 3 treatment on TDECs derived from a murine squamous cell carcinoma (TDEC SCC ) and a murine radiation-induced fibrosarcoma (TDEC RIF ), as well as normal endothelial cells derived from yolk sac (MYSEC) and aortic (MAE) tissues (Fig. 1) . Considerable variation was observed in responsiveness to the antiproliferative effects of 1,25-(OH) 2 D 3 among these endothelial cell types. As the doubling times for all four cell types were between 25-28 h, the large differences in sensitivity to 1,25-(OH) 2 D 3 that were observed cannot be accounted for by variations in growth rate. Interestingly, the two TDEC types were more sensitive than the endothelial cells from either normal tissue. In addition, the potency of 1,25-(OH) 2 D 3 on both TDEC SCC and TDEC RIF (IC 50 ϭ 2.6 and 10.9 nm, respectively) was comparable to what was observed for the corresponding tumor cells (3) .
Vitamin D analogs and combination treatments also inhibit TDEC proliferation
Since the hypercalcemia induced by 1,25-(OH) 2 D 3 limits the dose that can be given safely (17) (18) (19) , other vitamin Dbased therapies have also been considered, including use of vitamin D analogs with less propensity to increase serum calcium levels (24) Fig. 2A) . The combination of 1,25-(OH) 2 D 3 and DEX also had greater antiproliferative effects than either agent alone on TDEC SCC (Fig. 2B) . These results do not take into account the additional advantage that these strategies may allow higher doses to be given without dose-limiting hypercalcemia. 
Expression of VDR varies among endothelial cells of different origins
As we observed variations in the responsiveness to 1,25-(OH) 2 D 3 among endothelial cell types derived from different tissues, we examined whether the sensitivity to 1,25-(OH) 2 D 3 could be explained by differences in the expression of the VDR. We performed Western blots for VDR in four endothelial cell types after treatment with 1,25-(OH) 2 D 3 and/or DEX (Fig. 3) . Although the low levels of VDR found in MAE correlated with the relative resistance to 1,25-(OH) 2 D 3 , MYSEC expressed similar levels of VDR to TDECs after treatment with 1,25-(OH) 2 D 3 , but were significantly less sensitive, suggesting that other factors are involved. Furthermore, addition of DEX caused a further induction of VDR in TDEC SCC and TDEC RIF ; similar results have been observed in SCC cells (25) .
Effects of 1,25-(OH) 2 D 3 on key growth/survival signals and apoptosis in TDECs
We have also previously examined the effects of 1,25-(OH) 2 (Fig. 4A) . In contrast, 1,25-(OH) 2 D 3 had no effect on p21
Waf1 and p27 Kip1 in MAE. The addition of DEX had little effect on p21
Waf1 and p27 Kip1 in TDEC SCC , but did have a modest effect in MAE.
1,25-(OH) 2 D 3 treatment also caused a decrease in the levels of phosphorylated, active ERK and Akt and led to the hypophosphorylation of Rb in TDEC SCC (Fig. 4B) . These effects also occur in SCC cells and are consistent with a G 0 /G 1 cell cycle arrest (25) . These markers were unchanged in MAE cells treated with 1,25-(OH) 2 As 1,25-(OH) 2 D 3 has been shown to induce apoptosis in some cell types (2, 27) , including SCC cells (26), we examined whether induction of apoptosis contributes to the antiproliferative effects observed in TDEC SCC . A small increase in the 85-kDa PARP cleavage fragment, indicative of apoptosis, was observed in TDEC SCC treated with either 1,25-(OH) 2 D 3 or DEX compared with control, whereas the combination resulted in the same amount of PARP cleavage as the single agents (Fig. 4C) . Evidence of apoptosis in TDEC SCC after treatment with 1,25-(OH) 2 D 3 or the combination of 1,25-(OH) 2 D 3 and DEX was also observed using an annexin V binding assay; however, across multiple experiments, the extent of apoptosis was variable, and no statistically significant difference between 1,25-(OH) 2 D 3 alone and the combination was observed (data not shown). Further, no changes were observed in levels of the apoptotic regulators Bax, Bcl-2, and Fas ligand (data not shown). However, the expression of Fas and p53 was modulated. 1,25-(OH) 2 D 3 treatment led to an increase in Fas levels in TDEC SCC with little effect in MAE (Fig. 4C) . 1,25-(OH) 2 D 3 or DEX alone also induced p53 levels in TDEC SCC , whereas the effect of the combination was similar to the control level (Fig. 4C) . In contrast, DEX alone or in combination with 1,25-(OH) 2 D 3 caused a reduction in p53 in MAE, whereas 1,25-(OH) 2 D 3 alone had little effect.
1,25-(OH) 2 D 3 treatment decreases expression of Ang-2 in cancer cells
To test whether 1,25-(OH) 2 D 3 and DEX affect angiogenesis by modulating the expression of angiogenic signaling molecules, a targeted cDNA array containing 25 murine, angiogenesis-related genes (Nonrad-GEArray, SuperArray, Inc., Bethesda, MD) was used to assess changes in expression after treatment with 1,25-(OH) 2 D 3 and DEX. Although no significant differences were detected with 1,25-(OH) 2 D 3 treatment in TDEC SCC , Ang-2 levels were reduced in SCC cells after treatment with 1,25-(OH) 2 D 3 and DEX (data not shown). This result was confirmed by Western blot analysis of SCC whole cell lysates, which demonstrated that the modulation of Ang-2 levels also occurs at the protein level (Fig. 5) . The reduction was more dramatic after treatment with 1,25-(OH) 2 D 3 alone than after the combination of 1,25-(OH) 2 D 3 and DEX. Similar results were observed in RIF-1 cells (Fig. 5) .
In contrast to the immunohistochemistry studies by Iseki et al. (11) demonstrating that treatment with 1,25-(OH) 2 D 3 decreased the expression of VEGF in a colon cancer model, we did not detect a significant change in VEGF RNA levels in our array analysis (data not shown). However, VEGF was only expressed at low levels in untreated SCC cells; therefore, this model may not be optimal for exploring the effects of VEGF modulation.
Discussion
Despite strong evidence that 1,25-(OH) 2 D 3 has antitumor activity in a wide variety of tumor types, including prostate, colon, breast, and others (2, 28, 29) , it is still unclear how to translate these results into a useful therapeutic regimen in cancer patients. 1,25-(OH) 2 D 3 and vitamin D analogs are currently being evaluated in phase I and phase II clinical trials as both single agents and in combination with cytotoxic agents in a variety of cancer types. However, the most appropriate dose and schedule have not been defined, nor is it known which cancer types, let alone which individual patients, will respond to vitamin D-based therapies. Although clinical trials will certainly help to address these issues, information regarding the antitumor mechanism(s) of 1,25-(OH) 2 D 3 and vitamin D analogs would also be helpful. For example, recent evidence that some cytotoxic agents, such as paclitaxel (30) , vinca alkaloids (31), and camptothecins (32), also affect angiogenesis has led to new hypotheses about the most appropriate dosing strategies for these agents (33) . Similar ideas should be considered for 1,25-(OH) 2 D 3 if it also inhibits tumor angiogenesis.
In fact, there is considerable data to suggest that 1,25-(OH) 2 D 3 and vitamin D analogs can inhibit angiogenesis (9 -12) . However, it is also important to understand whether the antiangiogenic effects occur in both tumors and normal tissues, and whether these effects occur by direct actions on endothelial cells, via indirect effects on angiogenic signaling, or a combination of both mechanisms. Endothelial cells and the unique signaling pathways that they use have become attractive targets for new anticancer agents; therefore, understanding the mechanism(s) by which 1,25-(OH) 2 D 3 inhibits tumor angiogenesis would potentially allow a more rational basis for designing combination therapies involving such agents. Further, identification of the signaling pathways that are involved would potentially provide useful biomarkers of response to therapy, as has been proposed for other antiangiogenic agents (34) .
Previous studies have demonstrated various effects of 1,25-(OH) 2 D 3 on endothelial cell types derived from normal tissues (8, 12, (35) (36) (37) . However, endothelial cells within tumors are not the same as those in normal tissues; therefore, it is critical to use models that are representative of this unique setting when examining the effects of an agent on tumor angiogenesis. Although umbilical vein and aortic endothelial cells are commonly used to test agents for antiangiogenic effects, we and others have identified selective markers for TDECs (15, 16) , several of which are conserved in mice and humans (38) . In addition to these molecular differences, there are clear morphological differences between tumor vessels and normal vessels, as tumor vessels are more tortuous, leaky, and often lack pericytes (39 -41) . Thus, we examined the effects of 1,25-(OH) 2 D 3 on both TDECs and endothelial cells from normal tissues to determine whether there were differences in responsiveness to 1,25-(OH) 2 D 3 among endothelial cells of different origins.
In fact, considerable variation was observed in responsiveness to the antiproliferative effects of 1,25-(OH) 2 D 3 among these endothelial cell types. Interestingly, the two TDEC types were more sensitive than the endothelial cells from the normal tissues that were examined. Although the potency of 1,25-(OH) 2 Although the strong antiproliferative effects of the vitamin D analogs are promising for the clinical development of these compounds, these results may not provide much insight about the structural requirements for further analog optimization. For example, the antiproliferative activity of the analogs did not correlate with their VDR binding affinity, as all of the analogs have lower VDR affinity than the parent (with EB1089 being weakest) (44), but equivalent or stronger antiproliferative effects. On the other hand, our antiproliferative results roughly correlate with the ratio of VDR affinity to vitamin D-binding protein affinity (44) , at least for 7553, 6760, and 1,25-(OH) 2 D 3 . The affinity of EB1089 for vitamin D-binding protein, and therefore the ratio, are not known. However, several other factors are potentially important, such as their relative ability to enter cells, their catabolic inactivation, as well as their ability to stabilize VDR in a conformation that heterodimerizes with RXR, binds DNA, promotes binding of coactivators, and ultimately regulates transcription (45) . Several of these factors may also vary depending on the cell type or tissue being tested. Thus, although our results are not inconsistent with previous data, they could not have been easily predicted.
As we observed variations in the responsiveness to 1,25-(OH) 2 D 3 among endothelial cell types derived from different tissues, we examined whether the sensitivity to 1,25-(OH) 2 D 3 could be explained by differences in the expression of the VDR. As was the case in SCC cells (25) Both cell cycle and apoptotic effects were observed and probably contribute to the antiproliferative activity. Effects such as inhibition of the ERK and Akt pathways are of interest because they may sensitize the tumor endothelium to other chemotherapy agents (46, 47) and serve as potential biomarkers of response. On the other hand, the induction of p53 by 1,25-(OH) 2 D 3 in TDEC SCC differs from the decrease observed in SCC cells (Hershberger, P. A., T. F. McGuire, and C. S. Johnson, manuscript in preparation) and may be important in the rational design of combination therapies involving agents that act via p53-dependent mechanisms.
We also identified Ang-2 as a target molecule that is reduced in SCC and RIF-1 cells after treatment with 1,25-(OH) 2 D 3 . Ang-2 is an antagonist for the Tie-2 receptor (48); this ligand is overexpressed in a variety of tumors (49 -51) , and forced overexpression can promote tumor growth (52) . Furthermore, Ang-2 can promote endothelial cell survival via the Akt pathway (53) . Thus, the reduction in Ang-2 levels caused by 1,25-(OH) 2 D 3 may inhibit tumor angiogenesis and overall tumor growth.
In conclusion, we have demonstrated that 1,25-(OH) 2 D 3 alone or in combination with DEX can inhibit the proliferation of TDECs at low nanomolar concentrations, whereas two endothelial cell lines from normal tissues were significantly less sensitive. The expression of VDR could not completely explain these differences. In addition, three vitamin D analogs that have less propensity to induce hypercalcemia than 1,25-(OH) 2 D 3 were at least as potent as the parent compound. Furthermore, the effects of 1,25-(OH) 2 D 3 and DEX on signaling pathways, including ERK, Akt, and the cyclindependent kinase inhibitors, p21
Waf1 and p27 Kip1 , were similar to our previous observations in SCC cells, whereas p53 was induced only in the TDECs. In contrast, 1,25-(OH) 2 D 3 had minimal effects on these signaling molecules in MAE; therefore, there is considerable variation in the response of endothelial cells derived from different tissues. It will be interesting to note in future studies whether toxicities of 1,25-(OH) 2 D 3 occur in tissues in which the endothelial cells are relatively sensitive. Finally, 1,25-(OH) 2 D 3 also modulates the expression of Ang-2 in SCC and RIF-1 tumor cells, an effect that may inhibit tumor angiogenesis in vivo. Thus, our work supports the hypothesis that angiogenesis inhibition plays a role in the antitumor effects of vitamin D-based therapies, and that both direct effects on endothelial cells and indirect effects are involved. This information should be useful in the development of new combination therapies and in the design of future clinical trials.
